GreenLight Biosciences (NASDAQ:GRNA – Get Rating) is one of 251 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare GreenLight Biosciences to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.
Valuation and Earnings
This table compares GreenLight Biosciences and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| GreenLight Biosciences | $10.20 million | -$167.05 million | -0.25 |
| GreenLight Biosciences Competitors | $638.80 million | $65.91 million | -2.50 |
GreenLight Biosciences’ peers have higher revenue and earnings than GreenLight Biosciences. GreenLight Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Insider & Institutional Ownership
24.4% of GreenLight Biosciences shares are owned by institutional investors. Comparatively, 46.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 30.3% of GreenLight Biosciences shares are owned by company insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and price targets for GreenLight Biosciences and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GreenLight Biosciences | 0 | 1 | 2 | 0 | 2.67 |
| GreenLight Biosciences Competitors | 966 | 3633 | 9666 | 168 | 2.63 |
GreenLight Biosciences currently has a consensus target price of $4.50, indicating a potential upside of 1,450.65%. As a group, “Biological products, except diagnostic” companies have a potential upside of 82.43%. Given GreenLight Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe GreenLight Biosciences is more favorable than its peers.
Profitability
This table compares GreenLight Biosciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GreenLight Biosciences | -1,521.00% | -374.26% | -122.78% |
| GreenLight Biosciences Competitors | -4,693.66% | -133.49% | -43.70% |
Summary
GreenLight Biosciences peers beat GreenLight Biosciences on 7 of the 13 factors compared.
GreenLight Biosciences Company Profile
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
